The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...
This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care ...
Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope AMR is a leading cause of kidney transplant loss with no approved treatments U.S. IND previously ...
Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...
An investigational anti-CD38 monoclonal antibody (CM313) rapidly increased platelets in immune thrombocytopenia (ITP) patients to levels sufficient for preventing bleeding, a small single-arm Chinese ...
Acute graft-versus-host disease (aGVHD) is a life-threatening complication after allogeneic hematopoietic stem cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback